Merck May Sell Consumer Health Business

Sep 05, 2017

Merck is considering selling its consumer healthcare business, the German pharma company said on Tuesday.

While the business unit brings in annual sales of $1 billion, the company says it needs further funds to continue its research into prescription drugs to remain competitive. The company is in the early stages of a strategic review and will be considering a sale or strategic partnership. A final decision is expected early in 2018.

Merck has been focusing its healthcare division on drug development with a focus on cancer immunotherapy treatment Bavencio and multiple sclerosis pill Mavenclad.

The strategic review comes after declining sales of Merck's liquid crystals business, a supplier of the chemicals used in LCD screens.

Read the Reuters report